BOLT

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics, Inc. (BOLT) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Profitability (D-). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.3
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 82.6%
Price Return 12M 23.4%
Catalyst Signal 0.00
Market Cap $15.1M
TTM Revenue N/A
Price / Sales N/A
ROE N/A

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) C+ (2.5) D- (0.8) B (3.2) C+ (2.6) C (2.3)
2026-11-10 C+ (2.5) C+ (2.5) D- (0.8) B- (3.1) C+ (2.6) C (2.3)
2026-11-03 C+ (2.5) C+ (2.5) D- (0.8) C+ (2.6) C+ (2.7) C (2.2)
2026-10-27 B- (3.0) D+ (1.5) C (2.2) C+ (2.6) C+ (2.6) C (2.4)
2026-10-20 B- (3.0) D (1.4) C (2.2) C- (2.1) C+ (2.6) C (2.3)
Page 1 of 7